aTyr seeks to develop innovative therapeutics to address the unmet needs of patients by developing a novel class of biologic drugs. We have developed proprietary methods for discovering Physiocrines™, extracellular proteins that are derived from the tRNA synthetase family of enzymes, and which were predominantly overlooked by other genomic and secretome discovery efforts. aTyr’s proprietary discovery approach and expertise has enabled the exploration of this completely new class of biologic targets, and has allowed aTyr to establish a unique and comprehensive intellectual property portfolio across the Physiocrine family. We are currently developing a portfolio of Physiocrine therapeutic proteins, and focusing on indications in the areas of hematology, immune modulation, infection, and metabolism.
ARS are Expressed in Tissues at Varying Levels